Scroll Top

Therapy of relapsed-refractory multiple myeloma

Therapy of relapsed-refractory multiple myeloma

ASCO 2020 Ancillary Event

Chaired by Mohamad Mohty with Graham Jackson, María-Victoria Manteca, Suzanne Trudel and Salomon Manier, this 1 hour 45 minute webcast focuses on providing you with the best decision-making tools to select the optimal therapy for patients with relapsed-refractory multiple myeloma (RRMM). After taking part in the educational activity, you will know who, when, and how to treat RRMM.

Learning objectives

After participating in the webcast you will be able to:

  • Describe the advances in therapeutic targets in RRMM and the associated novel agents
  • Select optimal and individualized treatment strategies for patients with RRMM


  • Welcome and introduction
  • Relapse definition and timing of therapy
  • Optimal sequencing of therapy at first relapse
  • Optimal sequencing of therapy beyond first relapse
  • Trial results of anti-CD38 and bispecific antibodies
  • Trial results of conjugated antibodies
  • Faculty discussion and audience questions


Mohamad Mohty
Saint Antoine Hospital, University Pierre et Marie Curie, France

Mohamad Mohty is full Professor of Hematology and head of the Hematology and cellular therapy department at the Saint-Antoine Hospital and Sorbonne University (Paris, France). Professor Mohty is also head of a translational research team at the Saint-Antoine Research Centre in Paris and his research is focused on the pathophysiology and immunobiology of normal and pathological antigen-presenting cells, especially the impact of novel immunomodulatory agents such as proteasome inhibitors, IMiDs and hypomethylating agents. He has a special clinical focus on the development of reduced-toxicity conditioning regimens, immunotherapy and different aspects of therapy of acute leukemia and multiple myeloma. Professor Mohty is past-president of the European Society for Blood and Marrow Transplantation (EBMT), and the current chairman of the Acute Leukemia Working Party of EBMT. He is also the founder and chairman of the International Academy for Clinical Hematology (IACH) and serves on the board of the EBMT, and the Intergroupe Francophone du Myelome (IFM). He is also a member of the American Society of Hematology (ASH), American Society for Clinical Oncology (ASCO), American Society for Blood and Marrow Transplantation, European Hematology Association (EHA), and EBMT.

Professor Mohty obtained his medical degree from the University of Montpellier, France, and his PhD from the University of Marseille, France. He also undertook post-doctoral work at the Hematology Department, Imperial College, Hammersmith Hospital, London, UK. He has published more than 700 peer-reviewed articles in the field of stem cell transplantation, leukemia and myeloma, in different hematology and immunology journals. He also serves as Editor-in-Chief of the journals Bone Marrow Transplantation and Clinical Hematology International, and as Associate Editor for Leukemia, EJH, etc.

Grants/research support, honoraria/consultation fees from: Amgen, Celgene, Takeda, Sanofi, Janssen, BMS, Adaptive Biotechnologies

Graham Jackson
University of Newcastle, UK

Graham Jackson is a Consultant Hematologist at Newcastle Hospitals Trust, Newcastle upon Tyne, UK and is Professor of Hematology at Newcastle University, UK.

He is a former president of the British Society for Haematology (BSH) and the British Society of Blood and Marrow Transplantation (BSBMT) and has served twice on the council of the Royal College of Pathologists (RCPath). He has served on the Clinical Trials Advisory and Awards Committee (CTAAC) and on the Blood wise clinical trials committee. He has been a director of Myeloma UK and scientific secretary for the UK Myeloma Forum (UKMF).

Professor Jackson leads the myeloma service at the University of Newcastle upon Tyne/Newcastle Upon Tyne Hospitals trust. He has been CI on the MRC Myeloma 9 and 11 and is currently the CI for myeloma 11+ and 14. He is part of the safety monitoring committee for all the MUK trials and previously was on the Data Monitoring and Ethics Committee (DMEC) for the Endeavour and Clarion trials. His research interests focus on clinical trials and safety in the treatment of myeloma, development of long-term bone marrow transplant follow-up clinics, and the cytokine profile of acute and chronic graft-versus-host disease.

Throughout his career, Professor Jackson has received a number of awards, including a special fellowship to the European School of Hematology and European Community Fellowship to the European School of Oncology. He has won the Van Bekkum medal at the EBMT and has been awarded the BSH gold medal.

He graduated from Cambridge and the Westminster School of Medicine. He gained his MRCP in 1986 and then moved to Newcastle University to undertake his MD, which he completed in 1992. Professor Jackson obtained his MRCPath in 1993, followed by his FRCP in 1999 and his FRCPath in 2000. He has published over 200 peer reviewed papers as well as many book chapters and reviews.

Honoraria/consultation fees from: Celgene, Amgen Roche, Takeda, J&J, Oncopeptides and GlaxoSmithKline

María-Victoria Mateos
University of Salamanca, Spain

María-Victoria Mateos is Consultant Physician in the Hematology Department and Associate Professor of Medicine at the University of Salamanca, Spain. She is the director of the Myeloma Program and coordinates the Clinical Trials Unit in Salamanca’s University Hospital Hematology Department. Dr Mateos serves as coordinator of GEM (Spanish Myeloma Group), with direct involvement in the design and development of clinical trials. She has coordinated many clinical trials in elderly and smouldering multiple myeloma patients that have profoundly influenced current options for treating these patient populations. She is also a member of the IMWG (International MM Working Group), IMS (International MM Society), European Hematology Association (EHA) and American Society of Hematology (ASH).

Dr Mateos is Associate Editor of myeloma in Annals of Hematology since 2011 and has acted as a reviewer for top journals such as NEJM, Lancet and Lancet Oncology. Among her invited presentations, she has recently contributed to the educational sessions of EHA 2012, ASH 2013, ASCO 2015, EHA 2016, ASCO and ASH 2017. She has also served on the EHA’s Scientific Program Committee and Advisory Board since 2013 until 2017, and on the ASH Scientific Committee on plasma cell diseases 2015-2017. She is a Councilor on the EHA Board since 2015, for a four-year mandate, member of the Steering Committee for the Society of Hematologic Oncology (SOHO), and member of the IMS board and the European School of Hematology (ESH) scientific committee.

She has published over 200 papers in peer-reviewed international journals, some of which have become key references in the multiple myeloma field. Her areas of interest include multiple myeloma, the biology of plasma cells and the news drugs development.

Grants/research support, honoraria/consultation fees from: Janssen, Celgene, Takeda, Amgen, GlaxoSmithKline, Oncopeptides, Seattle Genetics, Roche, Adaptive, AbbVie, Pfizer and Regeneron

Salomon Manier
Lille University Hospital, France

Salomon Manier is an Associate Professor of Hematology at Lille University Hospital (France), where he also worked as an instructor in Medical Oncology (2015–2019) and in Hematology (2017-2019).

Dr Manier is member of the American Society of Hematology (ASH), European Hematology Association (EHA), International Myeloma Society (IMS), Société Française d’Hématologie (SFH), and board member of Intergroupe Francophone du Myelome (IFM). He is also part of the scientific committees of ASH on Plasma Cell Neoplasia and of the American Association for Cancer Research (AACR) in myeloma. Among his invited presentations, he has contributed to the educational sessions of ASH 2017 (chairman of a session), and EHA 2020 (myeloma section).

Dr Manier has also worked as co-editor of the international journal Current Research in Translational Medicine and is an ad-hoc reviewer in the journals Blood, Leukemia, and Blood Advances. Throughout his career, Dr Manier has received a number of awards, including IMS Travel Award (2017), EHA Travel Grant (2017), TRTH EHA/ASH Translational Research Training in Hematology (2018) Force Hemato Award (2019).

Dr Manier completed his MD in 2008 at University of Paris (France) and obtained his PhD in 2017 at University of Lille (France).

Grants/research support from: Celgene, Janssen

Suzanne Trudel
Princess Margaret Cancer Centre, Toronto, Canada

Suzanne Trudel is Associate Professor in the Department of Medicine at the University of Toronto, and Attending Physician at Princess Margaret Cancer Centre, Toronto, Canada. She is also a Clinician Scientist at the Ontario Cancer Institute, Canada.

Dr Trudel received her medical degree from the University of Toronto. Her training included postdoctoral fellowships at the University of Toronto and Weill Medical College at Cornell University. She holds certifications in hematology and internal medicine from the American Board of Internal Medicine as well as the Royal College of Physicians and Surgeons of Canada. Dr Trudel’s research is focused in the areas of molecular target identification and validation and development of novel biologically based therapies for multiple myeloma.

Grants from: Janssen, GlaxoSmithKline, BMS, Genentech, Amgen, Pfizer
Honoraria fees from: Janssen, Amgen, Celgene, Karyopharm, Takeda, Sanofi
Consultation fees from: BMS, Amgen Canada, GlaxoSmithKline


This program is targeted at Hematologists, oncologists, oncology nurses, and all other HCPs managing RRMM.

Educational grant

This educational activity is supported by an educational grant from GlaxoSmithKline.

healthcare professionals completing our programs
educational programs launched
countries receiving live education


Rebecca Cox

Principal Medical Education Writer

Related Programs |view all programs